Table 4.
Multivariate analysis on the EQ‐5D utility score and the EQ‐VAS score of esophageal cancer patients
| Variable |
EQ‐5D utility score β (95% CI) |
EQ‐VAS score β (95% CI) |
|---|---|---|
| Clinical stage, reference group: severe dysplasia/CIS | ||
| Stage I | −0.109** (−0.166, −0.051) | −3.784** (−6.464, −1.104) |
| Stage II | −0.114** (−0.172, −0.055) | −5.025** (−7.741, −2.309) |
| Stage III | −0.143** (−0.208, −0.080) | −7.453** (−10.374, −4.533) |
| Stage IV | −0.328** (−0.407, −0.249) | −13.087** (−16.440, −9.734) |
| Other chronic diseases, reference group: no | ||
| Yes | −0.033 (−0.079, 0.013) | −2.918** (−5.013, −0.823) |
| Therapeutic regimen, reference group: surgery | ||
| Radical resection | −0.043 (−0.106, 0.019) | −3.013* (−5.885, −0.141) |
| Radiotherapy | −0.123** (−0.197, −0.049) | −7.653** (−10.990, −4.315) |
| Chemotherapy | −0.066 (−0.138, 0.006) | −3.433* (−6.856, −0.010) |
| Surgery plus adjuvant chemotherapy | −0.145** (−0.246, −0.044) | −3.923 (−8.958, 1.112) |
| Concurrent chemoradiotherapy | −0.111* (−0.197, −0.026) | −5.484** (−9.266, −1.702) |
| Symptomatic treatment | −0.133** (−0.208, −0.058) | −6.042** (−9.719, −2.366) |
| Others | 0.403* (0.232, 0.574) | 8.693** (3.395, 13.990) |
| Marital status, reference group: married | ||
| Others | −0.139** (−0.236, −0.042) | −7.857** (−12.069, −3.645) |
In addition to what have been reported in the table, a set of study center dummies have also been included. Other respondents’ characteristics which were included in the regression but statistically insignificant (P > 0.05) include age, gender, occupation, and duration of illness.
P < 0.05;
P < 0.01.